MA41381A - Composés participant à une liaison coopérative et leurs utilisations - Google Patents

Composés participant à une liaison coopérative et leurs utilisations

Info

Publication number
MA41381A
MA41381A MA041381A MA41381A MA41381A MA 41381 A MA41381 A MA 41381A MA 041381 A MA041381 A MA 041381A MA 41381 A MA41381 A MA 41381A MA 41381 A MA41381 A MA 41381A
Authority
MA
Morocco
Prior art keywords
liaison
cooperative
compounds participating
participating
compounds
Prior art date
Application number
MA041381A
Other languages
English (en)
French (fr)
Inventor
Neville John Anthony
Brian Roger Bowman
Matthew James Nichols
Mathew Edward Sowa
Dylan Talbot Stiles
Sharon Ann Townson
Gregory Lawrence Verdine
Original Assignee
Warp Drive Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warp Drive Bio Inc filed Critical Warp Drive Bio Inc
Publication of MA41381A publication Critical patent/MA41381A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041381A 2015-01-09 2016-01-07 Composés participant à une liaison coopérative et leurs utilisations MA41381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562101925P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
MA41381A true MA41381A (fr) 2017-11-28

Family

ID=56356469

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041381A MA41381A (fr) 2015-01-09 2016-01-07 Composés participant à une liaison coopérative et leurs utilisations

Country Status (7)

Country Link
US (4) US10039839B2 (enExample)
EP (3) EP3247377A4 (enExample)
JP (5) JP2018507251A (enExample)
AR (1) AR105755A1 (enExample)
MA (1) MA41381A (enExample)
TW (1) TW201629069A (enExample)
WO (1) WO2016112279A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
CA3000822A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
US20200199102A1 (en) * 2017-04-05 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
WO2018187423A1 (en) * 2017-04-05 2018-10-11 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CN110730822B (zh) * 2017-04-18 2024-03-08 X-化学有限公司 鉴定化合物的方法
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN116083290B (zh) * 2022-11-21 2024-06-14 陕西省微生物研究所 一种铅锌和/或抗生素和/或抗性基因污染土壤修复的复合微生物菌剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2089723T3 (es) 1992-03-27 1996-10-01 American Home Prod 29-demetoxirapamicina para inducir la inmunodepresion.
WO1995008548A1 (en) 1993-09-20 1995-03-30 The Leland Stanford Junior University Recombinant production of novel polyketides
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
GB9410142D0 (en) 1994-05-20 1994-07-06 Univ Warwick Carbapenems
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6902913B2 (en) 1997-04-30 2005-06-07 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
GB9927191D0 (en) 1999-11-17 2000-01-12 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20070203168A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
JP5789190B2 (ja) 2008-09-24 2015-10-07 シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ 新規の遺伝子クラスター
RU2492181C2 (ru) 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2456777A2 (en) 2009-07-24 2012-05-30 Université Henri Poincaré - Nancy 1 Stambomycin and derivatives, their production and their use as drugs
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP5174971B2 (ja) 2009-10-22 2013-04-03 ペプチドリーム株式会社 ペプチド翻訳合成におけるｒａｐｉｄディスプレイ法
AU2011336727B2 (en) 2010-11-30 2016-11-03 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
US9260484B2 (en) * 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
CN106255882A (zh) 2014-03-03 2016-12-21 耶路撒冷希伯来大学伊森姆研究发展公司 用于检测铜绿假单胞菌的方法和装置
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
IL317393A (en) * 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses

Also Published As

Publication number Publication date
US20250121077A1 (en) 2025-04-17
EP3247377A4 (en) 2018-06-13
JP2022093718A (ja) 2022-06-23
EP3247377A1 (en) 2017-11-29
AR105755A1 (es) 2017-11-08
US10039839B2 (en) 2018-08-07
US20160199506A1 (en) 2016-07-14
JP2026015411A (ja) 2026-01-29
EP4545521A2 (en) 2025-04-30
JP2018507251A (ja) 2018-03-15
JP2020063256A (ja) 2020-04-23
US20180318434A1 (en) 2018-11-08
EP3757109A1 (en) 2020-12-30
TW201629069A (zh) 2016-08-16
JP2024149655A (ja) 2024-10-18
WO2016112279A1 (en) 2016-07-14
WO2016112279A8 (en) 2016-09-29
US20220143202A1 (en) 2022-05-12
EP4545521A3 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3897644A4 (en) CONNECTIONS INVOLVING IN A COOPERATIVE BINDING AND USES THEREOF
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
EP3649142A4 (en) JOINTS WITH SPLITABLE LINKER AND USES THEREOF
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
EP3529279A4 (en) CD133 BINDERS AND USE THEREOF
MA50618A (fr) Polyrhérapies et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
EP3352776A4 (en) Htt repressors and uses thereof
EP3328199A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
EP3325488A4 (en) CHIRAL DIARYLMA CROCYCLES AND USES THEREOF
EP3397757A4 (en) Novel CRISPR-ASSOCIATED TRANSPOSASES AND USES THEREOF
EP3344624A4 (en) Tyk2 inhibitors and uses thereof
MA52365A (fr) Composés et leurs utilisations
EP3768269A4 (en) CONNECTIONS AND USES THEREOF
EP3364958A4 (en) MODULATORS OF SESTRINE-GATOR2 INTERACTION AND USES THEREOF
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3347021A4 (en) CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MA45857A (fr) Composés et compositions, et utilisations associées
EP3399978A4 (en) Antiproliferative Compounds and their Pharmaceutical Compositions and Uses
EP3544606A4 (en) PSYCHOTROPE AGENTS AND USES THEREOF
MA41495A (fr) Composés benzoxaborole et leurs utilisations